Catalyst Crew Technologies Corp. (OTC: CCTC) announced today that it has submitted a corporate action request to the Financial Industry Regulatory Authority (FINRA) seeking approval to change its corporate name to LataMed AI Corp. and its trading symbol. The proposed name change is intended to better align the company's public identity with its new strategic direction, which focuses on artificial intelligence-enabled healthcare technology, including healthcare analytics and technology-enabled healthcare services infrastructure, with an initial emphasis on Latin America.
The corporate action was approved by the Company’s Board of Directors and by written consent of the Company’s majority shareholder in accordance with Nevada law. Importantly, the company noted that the proposed change does not involve any reverse stock split, forward stock split, recapitalization, change to authorized capital, or other modification to the capital structure. The issued and outstanding share count will remain unchanged, meaning shareholders’ ownership interests are unaffected and no action is required from them.
Upon FINRA approval, the company intends to file a Certificate of Amendment with the Nevada Secretary of State to effect the name change. The change would become effective upon completion of the required corporate filings and publication by FINRA on the Daily List. Dr. Kevin Rodan Levy, Chief Executive Officer, emphasized, “There is no change to the Company’s capital structure as part of this process. This proposed name change is intended to better align the Company’s public identity with its healthcare technology strategy and long-term market focus.”
The rebranding marks a significant step in Catalyst Crew Technologies’ transition from its previous identity to a company focused on digital health solutions for emerging markets. The company is actively executing its strategic transition into AI-enabled healthcare, pursuing opportunities in telehealth infrastructure, remote patient monitoring, healthcare data analytics, and integrated digital care platforms. More information about the company’s strategy can be found on its website at https://catalystcrewai.com and in its filings with the U.S. Securities and Exchange Commission at www.sec.gov.
The announcement underscores the company’s commitment to addressing the growing demand for modernized healthcare delivery systems in Latin America. However, there is no assurance that FINRA will approve the proposed name change, the requested new trading symbol, or the timing of any such approval. As a development-stage enterprise, the company has not generated revenues from its newly announced business direction, and there can be no assurance that it will successfully implement its business plan, complete acquisitions, secure financing, obtain regulatory approvals, or generate revenues.
The proposed name change to LataMed AI Corp. reflects a strategic pivot that could position the company to capitalize on the expanding healthcare technology market in Latin America, a region with significant unmet medical needs and growing digital infrastructure. If approved, the new name and symbol may enhance the company’s visibility among investors and partners focused on healthcare innovation in emerging markets.
